If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin® Therapies
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mLHumulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mLHumulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mLHumulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What are the pharmacodynamic properties of Humulin® (insulin human) and HUMALOG® (insulin lispro)?
The pharmacodynamic properties of insulin and insulin analogs may vary considerably in different individuals or within the same individual.
General Information
- The time course of action of insulin and insulin analogs may vary considerably in different individuals or within the same individual.1,2
- As with all insulins, the duration of action of the specific insulin product is dependent on site of injection, injection site blood supply, temperature, meal pattern, coadministered medications, physical activity, and renal or hepatic function.1,2
Humalog® (insulin lispro injection)-Specific Information
- Products containing Humalog® (insulin lispro injection) differ from regular human insulin because of their rapid onset of action as well as a shorter duration of activity. When used as a mealtime insulin, the dose of Humalog should be given within 15 minutes before or immediately after the meal.1
- Doses of the Humalog premixtures (Humalog® Mix50/50 [insulin lispro protamine and insulin lispro injectable suspension] or Humalog® Mix75/25 [insulin lispro protamine and insulin lispro injectable suspension]) should be given within 15 minutes before a meal.3,4
- One unit of Humalog has the same glucose-lowering effect as 1 unit of regular human insulin, but its effect is more rapid and of shorter duration.1 Additional information may be found in the prescribing information for the specific Humalog product.
Pharmacodynamic Properties of Lilly Insulin Products
Product |
Onset |
Dose (units/kg)a |
Time to Peak Insulin Concentrationb |
Duration |
Humalog |
More rapid onset than regular human insulin |
0.1-0.4 |
30 to 90 minutes |
Shorter than regular human insulin |
U-100R |
Approximately 30 minutes (10 to 75 minutes) |
0.05-0.4 |
36 to 150 minutes |
Approximately 8 hours (range, 3 to 14 hours) |
U-500R |
Less than 15 minutes |
0.4-0.6 and 0.8-1.3 |
21 hours (range, 13 to 24 hours)e |
|
LM75/25f |
More rapid than regular human insulin |
0.3 |
1 hour (30 minutes to 4 hours) |
22 hours (range, 13 to 22 hours) |
HI70/30g |
Approximately 50 minutes (range, 30 to 90 minutes) |
0.3 |
2.2 hours (1 to 5 hours) |
Approximately 23 hours (range, 18 to 24 hours) |
LM50/50f |
More rapid than regular human insulin |
0.3 |
1 hour (45 minutes to 13.5 hours) |
22 hours (range, 11 to 22 hours) |
NPH |
Slower than regular human insulin |
0.4 |
4 hours (1 to 12 hours) |
Longer than regular human insulin, up to 24 hours |
Abbreviations: HI70/30 = Humulin® 70/30 (human insulin isophane suspension and human insulin injection); Humalog = Humalog® (insulin lispro injection); LM50/50 = Humalog® Mix50/50 (insulin lispro protamine and insulin lispro injectable suspension); LM75/25 = Humalog® Mix75/25 (insulin lispro protamine and insulin lispro injectable suspension); NPH = Humulin N® (isophane insulin human suspension); U- 100R = Humulin® R U-100 (insulin human injection) 100 units/mL; U-500R = Humulin® R U-500 (insulin human injection) 500 units/mL.
aEuglycemic clamp study of healthy subjects.
bData presented as median (range) if available.
c0.4-0.6 units/kg.
d0.8-1.3 units/kg.
eCredited to the high concentration of the preparation.
fHumalog Mix products are a mixture of insulin lispro, a rapid-acting insulin, and insulin lispro protamine suspension, an intermediate-acting insulin.
gHumulin 70/30 is a mixture of human insulin isophane suspension, an intermediate-acting insulin, and regular human insulin, a rapid-acting insulin.
Enclosed Prescribing Information
References
1Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
2Humulin R U-100 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
3Humalog Mix50/50 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
4Humalog Mix75/25 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
5Humulin R U-500 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
6Humulin N [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
7Humulin 70/30 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: November 12, 2023